PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>CJC-1295 with DAC
Minimal evidence WADA prohibitedGH / growth factors

CJC-1295 with DAC

A modified GHRH 1-29 analog with a drug-affinity complex (DAC) lysine linker that enables albumin binding and an extended half-life, intended for sustained GH stimulation.

CompoundCJC-1295 with DAC
CategoryGHRH analog (long-acting)
ClassGrowth Hormone and Growth Factors
Evidence tierMinimal evidence
WADA statusProhibited in sport (or falls under a prohibited class) — see the WADA reference table
Sold on this siteNo — this is a reference database

Overview

This entry covers CJC-1295 with DAC, a ghrh analog (long-acting), graded "Minimal evidence" in this catalog's evidence system. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.

A modified GHRH 1-29 analog with a drug-affinity complex (DAC) lysine linker that enables albumin binding and an extended half-life, intended for sustained GH stimulation.

Mechanism of Action

Like native GHRH, CJC-1295 acts on pituitary GHRH receptors to stimulate GH secretion in pulses; the DAC modification stretches plasma residence to roughly 6–8 days.

Research and Evidence

A handful of early human pharmacology studies exist, but no registrational program was completed. The compound circulates almost entirely as a research chemical.

Evidence in context: the Growth Hormone and Growth Factors class page collects the shared evidence themes and study-reading guidance for this category.

Safety and Side Effects

No systematic human safety data for chronic use; prohibited in sport as a growth hormone releasing factor.

Educational notice: this entry describes published research and, where they exist, regulator labels. It is not medical advice and not a recommendation for use. Research-grade compounds have no verified human-safety data.

Frequently Asked Questions

What is the evidence tier of CJC-1295 with DAC?

CJC-1295 with DAC is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.

Is CJC-1295 with DAC an approved medicine?

No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.

Where can I read the primary studies for CJC-1295 with DAC?

The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.

References

  1. ClinicalTrials.gov — search for CJC-1295 studies. [source]
  2. WADA Prohibited List. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement